InVivo Therapeutics Holdings Corporation
InVivo Therapeutics Holdings Corporation (NVIV) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
nviv · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
InVivo Therapeutics Holdings CorporationYou NVIV | $1M | N/A | — | -$6.62 |
 Accelerate Diagnostics, Inc. AXDX | $1M | N/A | — | -$2.15 |
 Bellicum Pharmaceuticals, Inc. BLCM | $1M | N/A | — | -$0.81 |
 CohBar, Inc. CWBR | $1M | N/A | — | -$4.13 |
 Altamira Therapeutics Ltd. CYTO | $1M | N/A | — | $0.00 |
 HTG Molecular Diagnostics, Inc. HTGMQ | $0M | N/A | — | -$24.28 |
 Impel Pharmaceuticals Inc. IMPL | $1M | N/A | — | -$5.52 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for InVivo Therapeutics Holdings Corporation (NVIV) measures how much investors pay for each dollar of the company's trailing earnings. NVIV's current PE ratio of N/A is calculated by dividing its stock price of $0.32 by its TTM earnings per share of -$6.62.
Frequently asked questions
NVIV pe ratio · 6 questionsNVIV's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.32 and TTM EPS of -$6.62. Data sourced from Financial Modeling Prep via NVIV's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · InVivo Therapeutics Holdings Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09